Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer
But Competition Will Be Fierce
GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.
You may also be interested in...
Moderna Peers Into Post-Pandemic Future For Respiratory Vaccines
The company had its fourth vaccines day, where it talked about its strategy over the next few years for vaccines against COVID-19, RSV, flu and combinations thereof.
GSK Ends Pact with Vir For New COVID Treatments
Its Xevudy partner GSK is pulling out but Vir is going to carry on looking for new COVID-19 solutions independently, or with other partners.
Sobi Maintains Grip On RSV Market – For Now
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.